Zacks Investment Research upgraded shares of MacroGenics (NASDAQ:MGNX) from a sell rating to a hold rating in a report released on Tuesday, February 13th.
According to Zacks, “MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. “
Several other research firms have also recently weighed in on MGNX. BidaskClub raised MacroGenics from a strong sell rating to a sell rating in a research report on Thursday, January 25th. Cowen reissued a buy rating on shares of MacroGenics in a research report on Wednesday, January 24th. SunTrust Banks reissued a buy rating and issued a $31.00 price objective on shares of MacroGenics in a research report on Tuesday, January 23rd. BTIG Research reaffirmed a buy rating and issued a $28.00 target price on shares of MacroGenics in a research report on Tuesday, January 23rd. Finally, ValuEngine raised MacroGenics from a strong sell rating to a sell rating in a research report on Friday, December 1st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and nine have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $30.60.
MacroGenics (NASDAQ MGNX) traded down $0.21 on Tuesday, hitting $22.99. The stock had a trading volume of 192,700 shares, compared to its average volume of 221,953. MacroGenics has a 12 month low of $14.36 and a 12 month high of $24.26.
In other news, SVP Eric Blasius Risser sold 3,000 shares of the firm’s stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $22.50, for a total value of $67,500.00. Following the completion of the sale, the senior vice president now directly owns 12,100 shares in the company, valued at $272,250. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Jon Marc Wigginton sold 5,000 shares of MacroGenics stock in a transaction dated Wednesday, January 17th. The stock was sold at an average price of $20.00, for a total value of $100,000.00. The disclosure for this sale can be found here. 8.30% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Legal & General Group Plc increased its holdings in shares of MacroGenics by 4.3% during the 2nd quarter. Legal & General Group Plc now owns 7,925 shares of the biopharmaceutical company’s stock worth $138,000 after acquiring an additional 328 shares during the last quarter. Parametric Portfolio Associates LLC bought a new stake in shares of MacroGenics during the 2nd quarter valued at $203,000. Teacher Retirement System of Texas bought a new stake in shares of MacroGenics during the 4th quarter valued at $225,000. Virtu KCG Holdings LLC bought a new stake in shares of MacroGenics during the 2nd quarter valued at $232,000. Finally, MetLife Investment Advisors LLC bought a new stake in shares of MacroGenics during the 4th quarter valued at $281,000. Hedge funds and other institutional investors own 85.30% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Upgrades MacroGenics (MGNX) to Hold” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/22/macrogenics-mgnx-rating-increased-to-hold-at-zacks-investment-research.html.
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
Get a free copy of the Zacks research report on MacroGenics (MGNX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.